tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GPCR Stock Latest News

Structure Therapeutics Reports Q3 2025 Financial Results
Company AnnouncementsStructure Therapeutics Reports Q3 2025 Financial Results
4d ago
GPCR
Buy Rating for Structure Therapeutics: Potential Breakthrough in Obesity Treatment with Aleniglipron
PremiumRatings
Buy Rating for Structure Therapeutics: Potential Breakthrough in Obesity Treatment with Aleniglipron
4d ago
GPCR
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Q3 Earnings Cheat Sheet
PremiumPre-Earnings
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Q3 Earnings Cheat Sheet
5d ago
GPCR
Positive Buy Rating for Structure Therapeutics Driven by Promising Product Outlook and Strong Financial Position
PremiumRatings
Positive Buy Rating for Structure Therapeutics Driven by Promising Product Outlook and Strong Financial Position
8d ago
GPCR
Promising Market Potential for Structure Therapeutics’ Aleniglipron Driven by Positive Clinical Trials and Strategic Advantages
PremiumRatings
Promising Market Potential for Structure Therapeutics’ Aleniglipron Driven by Positive Clinical Trials and Strategic Advantages
10d ago
GPCR
Citi adds ‘positive 90-day catalyst watch’ on Structure Therapeutics
PremiumThe FlyCiti adds ‘positive 90-day catalyst watch’ on Structure Therapeutics
12d ago
GPCR
Strong Market Demand and Convenience Drive Buy Rating for Structure Therapeutics
Premium
Ratings
Strong Market Demand and Convenience Drive Buy Rating for Structure Therapeutics
16d ago
GPCR
Buy Rating for Structure Therapeutics: Aleniglipron’s Market Potential and Acquisition Appeal
Premium
Ratings
Buy Rating for Structure Therapeutics: Aleniglipron’s Market Potential and Acquisition Appeal
2M ago
GPCR
Promising Market Potential for Structure Therapeutics: Buy Rating Backed by Superior Trial Results and Market Opportunities
PremiumRatings
Promising Market Potential for Structure Therapeutics: Buy Rating Backed by Superior Trial Results and Market Opportunities
2M ago
GPCR
Optimistic Buy Rating for Structure Therapeutics Driven by Aleniglipron’s Potential in Obesity and T2D Markets
PremiumRatings
Optimistic Buy Rating for Structure Therapeutics Driven by Aleniglipron’s Potential in Obesity and T2D Markets
2M ago
GPCR
Structure Therapeutics price target lowered to $90 from $92 at Guggenheim
PremiumThe Fly
Structure Therapeutics price target lowered to $90 from $92 at Guggenheim
3M ago
GPCR
Structure Therapeutics price target raised to $75 from $60 at H.C. Wainwright
PremiumThe Fly
Structure Therapeutics price target raised to $75 from $60 at H.C. Wainwright
3M ago
LLY
GPCR
Structure Therapeutics price target lowered to $44 from $60 at Leerink
PremiumThe FlyStructure Therapeutics price target lowered to $44 from $60 at Leerink
3M ago
GPCR
Structure Therapeutics price target lowered to $87 from $89 at Citizens JMP
Premium
The Fly
Structure Therapeutics price target lowered to $87 from $89 at Citizens JMP
3M ago
GPCR
Structure Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Structure Therapeutics Reports Q2 2025 Financial Results
3M ago
GPCR
Promising Developments in Structure Therapeutics’ Clinical Trials Drive Buy Rating
PremiumRatings
Promising Developments in Structure Therapeutics’ Clinical Trials Drive Buy Rating
3M ago
GPCR
Structure Therapeutics files automatic mixed securities shelf
PremiumThe Fly
Structure Therapeutics files automatic mixed securities shelf
3M ago
GPCR
Structure Therapeutics initiated with a Buy at Clear Street
PremiumThe Fly
Structure Therapeutics initiated with a Buy at Clear Street
4M ago
GPCR
Structure Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
PremiumThe Fly
Structure Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
4M ago
GPCR
Structure Therapeutics Holds 2025 Annual Shareholders Meeting
PremiumCompany AnnouncementsStructure Therapeutics Holds 2025 Annual Shareholders Meeting
5M ago
8K
GPCR
Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating
Premium
Ratings
Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating
5M ago
GPCR
Structure Therapeutics price target raised to $80 from $75 at H.C. Wainwright
Premium
The Fly
Structure Therapeutics price target raised to $80 from $75 at H.C. Wainwright
6M ago
GPCR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >